cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Cue Biopharma Inc
4 own
5 watching
Current Price
$2.36
$0.13
(5.83%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
162.78M
52-Week High
52-Week High
5.12000
52-Week Low
52-Week Low
2.18000
Average Volume
Average Volume
0.35M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization162.78M
icon52-Week High5.12000
icon52-Week Low2.18000
iconAverage Volume0.35M
iconDividend Yield--
iconP/E Ratio--
What does the Cue Biopharma Inc do?
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Cue Biopharma Inc make?
News & Events about Cue Biopharma Inc.
Globe Newswire
5 months ago
BOSTON, April 12, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.(Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patients body, announced today the appointment of ...
Ticker Report
6 months ago
Cue Biopharma (NASDAQ:CUE Get Rating)s stock had its outperform rating restated by investment analysts at Oppenheimer in a report released on Wednesday, Benzinga reports. They presently have a $10.00 price target on the stock. Oppenheimers target price points to a...
Globe Newswire
6 months ago
BOSTON, March 15, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.(Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patients body, announced todaythat it will host a ...
Globe Newswire
7 months ago
BOSTON, March 01, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.(Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patients body, announced today that it will take ...
Globe Newswire
7 months ago
BOSTON, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.(Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patients body, announced today a collaboration and ...
Frequently Asked Questions
Frequently Asked Questions
What is Cue Biopharma Inc share price today?
plus_minus_icon
Can Indians buy Cue Biopharma Inc shares?
plus_minus_icon
How can I buy Cue Biopharma Inc shares from India?
plus_minus_icon
Can Fractional shares of Cue Biopharma Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Cue Biopharma Inc stocks?
plus_minus_icon
What is today’s traded volume of Cue Biopharma Inc?
plus_minus_icon
What is today’s market capitalisation of Cue Biopharma Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Cue Biopharma Inc?
plus_minus_icon
What percentage is Cue Biopharma Inc down from its 52-Week High?
plus_minus_icon
What percentage is Cue Biopharma Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$2.36
$0.13
(5.83%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
KINNATE BIOPHARMA INC
KINNATE BIOPHARMA INC
$1.39
$-0.05 (-3.47 %)
Fulcrum Therapeutics Inc
Fulcrum Therapeutics Inc
$4.41
$0.21 (5.00 %)
Annexon Inc
Annexon Inc
$2.45
$-0.04 (-1.61 %)
ADC Therapeutics SA
ADC Therapeutics SA
$0.90
$0.09 (11.11 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
KINNATE BIOPHARMA INC
KINNATE BIOPHARMA INC
$1.39
$-0.05 (-3.47 %)
Fulcrum Therapeutics Inc
Fulcrum Therapeutics Inc
$4.41
$0.21 (5.00 %)
Annexon Inc
Annexon Inc
$2.45
$-0.04 (-1.61 %)
ADC Therapeutics SA
ADC Therapeutics SA
$0.90
$0.09 (11.11 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Foreside Fund Services acts as the distributor to the DriveWealth ICE 100 Index ETF and is not affiliated with Borderless Investing Inc, DriveWealth LLC, BlackOak Investors LP, ACR Group, or other entities referenced on this website.

              Get Started with as little as $1.00